Eisai Inc., of Woodcliff Lake, N.J., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co. Ltd., appointed Harald Hampel vice president, global medical affairs and Michael Irizarry vice president, clinical research. Hampel will be responsible for creating and overseeing the company's global Alzheimer's disease (AD)/dementia medical strategies.